Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

N. Beije; J. Kraan; W. Taal; B. van der Holt; H.M. Oosterkamp; A.M. Walenkamp; L. Beerepoot; M. Hanse; M.E. van Linde; A. Otten; R.M. Vernhout; F.Y.F. de Vos; J.W. Gratama; S. Sleijfer; M.J. van den Bent

doi:https://doi.org/10.1038/bjc.2015.191

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

N. Beije, J. Kraan, W. Taal, B. van der Holt, H.M. Oosterkamp, A.M. Walenkamp, L. Beerepoot, M. Hanse, M.E. van Linde, A. Otten, R.M. Vernhout, F.Y.F. de Vos, J.W. Gratama, S. Sleijfer, M.J. van den Bent

Medical oncology (VUmc)

Research output: Contribution to journal › Article › Academic › peer-review

14 Citations (Scopus)

Original language	Undefined/Unknown
Pages (from-to)	226-231
Journal	British journal of cancer
Volume	113
Issue number	2
DOIs	https://doi.org/10.1038/bjc.2015.191
Publication status	Published - 2015

Access to Document

https://doi.org/10.1038/bjc.2015.191

Cite this

Beije, N., Kraan, J., Taal, W., van der Holt, B., Oosterkamp, H. M., Walenkamp, A. M., Beerepoot, L., Hanse, M., van Linde, M. E., Otten, A., Vernhout, R. M., de Vos, F. Y. F., Gratama, J. W., Sleijfer, S., & van den Bent, M. J. (2015). Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. British journal of cancer, 113(2), 226-231. https://doi.org/10.1038/bjc.2015.191

@article{9d65febe15014828b38b23f24587a53c,

title = "Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial",

author = "N. Beije and J. Kraan and W. Taal and {van der Holt}, B. and H.M. Oosterkamp and A.M. Walenkamp and L. Beerepoot and M. Hanse and {van Linde}, M.E. and A. Otten and R.M. Vernhout and {de Vos}, F.Y.F. and J.W. Gratama and S. Sleijfer and {van den Bent}, M.J.",

year = "2015",

doi = "https://doi.org/10.1038/bjc.2015.191",

language = "Undefined/Unknown",

volume = "113",

pages = "226--231",

journal = "British journal of cancer",

issn = "0007-0920",

publisher = "Nature Publishing Group",

number = "2",

}

Beije, N, Kraan, J, Taal, W, van der Holt, B, Oosterkamp, HM, Walenkamp, AM, Beerepoot, L, Hanse, M, van Linde, ME, Otten, A, Vernhout, RM, de Vos, FYF, Gratama, JW, Sleijfer, S & van den Bent, MJ 2015, 'Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial', British journal of cancer, vol. 113, no. 2, pp. 226-231. https://doi.org/10.1038/bjc.2015.191

Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. / Beije, N.; Kraan, J.; Taal, W. et al.
In: British journal of cancer, Vol. 113, No. 2, 2015, p. 226-231.

Research output: Contribution to journal › Article › Academic › peer-review

TY - JOUR

T1 - Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial

AU - Beije, N.

AU - Kraan, J.

AU - Taal, W.

AU - van der Holt, B.

AU - Oosterkamp, H.M.

AU - Walenkamp, A.M.

AU - Beerepoot, L.

AU - Hanse, M.

AU - van Linde, M.E.

AU - Otten, A.

AU - Vernhout, R.M.

AU - de Vos, F.Y.F.

AU - Gratama, J.W.

AU - Sleijfer, S.

AU - van den Bent, M.J.

PY - 2015

Y1 - 2015

U2 - https://doi.org/10.1038/bjc.2015.191

DO - https://doi.org/10.1038/bjc.2015.191

M3 - Article

C2 - 26042933

SN - 0007-0920

VL - 113

SP - 226

EP - 231

JO - British journal of cancer

JF - British journal of cancer

IS - 2

ER -

Beije N, Kraan J, Taal W, van der Holt B, Oosterkamp HM, Walenkamp AM et al. Prognostic value and kinetics of circulating endothelial cells in patients with recurrent glioblastoma randomised to bevacizumab plus lomustine, bevacizumab single agent or lomustine single agent. A report from the Dutch Neuro-Oncology Group BELOB trial. British journal of cancer. 2015;113(2):226-231. doi: https://doi.org/10.1038/bjc.2015.191